PDF (389.9 KB)
Collect
Submit Manuscript
Show Outline
Outline
Abstract
Keywords
References
Show full outline
Hide outline
Publishing Language: Chinese

The Dilemma and Way Out of Patent Regulation for Gene-Edited Crops

Institute for Chinese Legal Modernization Studies of Nanjing Normal University, Nanjing 210023
Show Author Information

Abstract

Gene-edited crops, the product of the intersection between biotechnology and agricultural science, represent a crucial direction in the development of modern agriculture. With the rapid advancement of the CRISPR-Cas9 system, the scientific research and commercial development of crop trait improvement have gradually shifted towards a “technology-driven” path, which has not only overturned traditional crop cultivation methods but also fundamentally propelled humanity's exploration of crop research. Nevertheless, the phenomenon of patenting fundamental research tools has sparked widespread controversy within academia and profoundly impacted the sharing and utilization of crop resources. Private entities patenting CRISPR-Cas9 technology restrict other researchers and farmers' opportunities to explore and harness genetic resources. This practice not only hinders scientific progress but also violates the fundamental consensus that genetic resources should be shared by all humanity. The sharing and openness of crop resources are crucial for the sustainable development of global agriculture and ecological balance, serving as a necessary condition for safeguarding public interests. A key issue that the governance of biotechnology patents urgently needs to address is how to reasonably allocate benefits and risks among traditional communities, researchers, research investors, and the public. This is also essential for constructing a new scientific ethics framework and regulating emerging technologies. However, China's policy responses in this area are still insufficient. To mitigate the negative effects stemming from the exclusivity of patents, it is imperative to reassess and reconstruct the framework of relevant systems. Firstly, we should adhere to the principle of moral utility, emphasizing the public nature of scientific research and its social responsibilities, while carefully considering the “harmful” nature of inventions to social morality. Secondly, implementing a mandatory disclosure system for biological genetic resources is a crucial step towards achieving transparency and fairness, with “applicants truthfully disclosing the actual origin of crop genes based on the principle of good faith” elevated to a mandatory norm. Lastly, the open licensing of fundamental patented technologies can draw inspiration from the experience of open-source software, encouraging more researchers to participate in the exploration of crop resources through the open sharing of research tools, thereby facilitating broader scientific collaboration and the transformation of research outcomes.

References

[1]
NEW EUROPE. 34 Nobel Prize winners jointly beg! What will Europe choose? (2024-01-21) [2024-07-20]. https://www.163.com/dy/article/IP0O9GOS05148KED.html. (in Chinese)
[2]
THOMAS J. Letter to Samuel Kercheval. (1816-07-12) [2024-07-20]. https://classicliberal.tripod.com/jefferson/kercheval.html.
[3]
HOLMAN C M. A fractured international response to CRISPR-enabled gene editing of agricultural products. Biotechnology Law Report, 2019, 38(1): 3-23.
[4]
XIAO X J. An analysis of the ethics of transgenic technology-from the view point of biological integrity. Social Sciences in China, 2016(6): 66-86. (in Chinese)
[5]
ZHANG Q. Ecological and ethical review of safety issues of genetically modified technologies and paths to avoidance. People's Tribune, 2013(23): 168-170. (in Chinese)
[6]
LI C, CAO W G. Advances in CRISPR/Cas9-mediated gene editing. Chinese Journal of Biotechnology, 2015, 31(11): 1531-1542. (in Chinese)
[7]
WANG J Y, DOUDNA J A. CRISPR technology: A decade of genome editing is only the beginning. Science, 2023, 379(6629): eadd8643.
[8]
LI H J, JIA Y N, ZHANG Y J, WANG X R, CHEN L M. Regulatory status of GM and gene-edited crops at domestic and abroad. Journal of China Agricultural University, 2023, 28(9): 1-11. (in Chinese)
[9]
MARC G. Gene editing in translational research. Revista de Bioética y Derecho, 2019(2019): 5-16.
[10]
JOSEP S P. Gene editing. Time to reflection. Revista de Bioética y Derecho, 2017(40): 157-166.
[11]
NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE. Preparing for future products of biotechnology. Washington, DC: The National Academies Press, 2017.
[12]
ESVELT K M, GEMMELL N J. Conservation demands safe gene drive. PLoS Biology, 2017, 15(11): e2003850.
[13]
JAI A D, CHRISTOPHER S R. Limping along and lagging behind: The law and emerging gene technologies. James Cook University Law Review, 2018(24): 61-76.
[14]
LI X, LIU X X, ZHANG W F. Supervision dynamic and development tendency of global agricultural gene editing technology. Chinese Bulletin of Life Sciences, 2023, 35(2): 114-122. (in Chinese)
[15]
OLUWATOBILOBA M. Addressing biopiracy through an access and benefit sharing regime-complex: In search of effective protection for traditional knowledge associated with genetic resources. Asper Review of International Business and Trade Law, 2016(16): 231-278.
[16]
ZOU W N, YUN G L, SONG M. Current situation and implications of innovation value chain in global gene editing breeding. Journal of China Agricultural University, 2023, 28(9): 12-23. (in Chinese)
[17]
KOZUBEK J. Crispr-Cas9 is impossible to stop. Georgetown Journal of International Affairs, 2017, 18(2): 112-119.
[18]
JAPANESE NHK “GENOME EDITING” INTERVIEW TEAM. Gene Magic Scissors: New Technology for Transforming Life. Translated by XIE Y L. Hangzhou: Zhejiang University Press, 2017. (in Chinese)
[19]
FAN Y L, WANG B, YU J R. Analysis on the patent layout of main applicants in China and abroad for CRISPR-Cas gene editing technology. Chinese Bulletin of Life Sciences, 2022, 34(10): 1305-1316. (in Chinese)
[20]
ZHOU J Z, ZHANG L, TANG C Y. Intellectual property rights and technology innovation: Linkage and effectiveness. R&D Management, 2006, 18(5): 106-112. (in Chinese)
[21]
DOUDNA J A, CHARPENTIER E. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014, 346(6213): e1258096.
[22]
CONG L, RAN F A, COX D, LIN S L, BARRETTO R, HABIB N, HSU P D, WU X B, JIANG W Y, MARRAFFINI L A, ZHANG F. Multiplex genome engineering using CRISPR/Cas systems. Science, 2013, 339(6121): 819-823.
[23]
FELDMAN R. The CRISPR revolution: What editing human DNA reveals about the patent system's DNA. UCLA Law Review Discourse, 2016(64): 392-411.
[24]
JON C. CRISPR patent ruling leaves license holders scrambling: widely anticipated decision affirms broad institute's claim to genome editing in human cells, but the battle is not over. Science, 2017, 6327(355): 786.
[25]
JACOB S S. The CRISPR patent decision didn't get the science right. That doesn't mean it was wrong. (2018-09-11) [2024-05-20]. https://www.statnews.com/2018/09/11/crispr-patent-decision-science/.
[26]
BIBIANA C. Who owns CRISPR? C&EN Global Enterprise, 2017, 8(95): 3.
[27]
HARRISON C. EPO revokes Broad's CRISPR patent. Nature Biotechnology, 2018, 36(3): 209.
[28]
McDONNELL B H, BERGHOFF LLP, KEVIN N. Sigma-Aldrich and broad propose preliminary motions in recent CRISPR interference No.106, 133, JDSUPRA. (2021-12-16) [2024-06-07]. https://www.jdsupra.com/legalnews/sigma-aldrich-and-broad-propose-6553124.
[29]
EMILY N R. The future of biotechnology: Accelerating gene-editing advancements through non-exclusive licenses and open-source access of CRISPR-Cas9. Santa Clara High Technology Law Journal, 2022, 1(38): 95-121.
[30]
LEDFORD H. Major CRISPR patent decision won't end tangled dispute. Nature, 2022, 603(7901): 373-374.
[31]
HARRISON C. UC's latest CRISPR patent. Nature Biotechnology, 2019, 37(1): 6.
[32]
STARLING S. CRISPR patent results. Nature Reviews Microbiology, 2017(15): 194.
[33]
VANDANA S. Bioprivacy: The plunder of nature and knowledge. Translated by LI Y D. Beijing: Intellectual Property Publishing House Co., Ltd. Press, 2018. (in Chinese)
[34]
ZHOU S H, WANG S P. Impacts of patent protection for DNA fragment on basic research and solutions to such problem. Science & Technology Progress and Policy, 2007, 24(3): 13-15. (in Chinese)
[35]
LI Y H. Ethical risks of gene-edited foods and rule of law responses. Social Sciences in Guangxi, 2023(7): 98-106. (in Chinese)
[36]
HU B. Ethic basis of patent law: From the perspective of patent problem of biotechnology. Law and Social Development, 2008(2): 109-122. (in Chinese)
[37]
SHI J Y, LIU Z X. Risk response to gene editing technology: Ethical governance and legal regulation. Research on Rule of Law, 2023(1): 86-98. (in Chinese)
[38]
KEAY L A. Morality's move within U.S. patent law: From moral utility to subject matter. AIPLA Quarterly Journal, 2012, 40(3): 409-439.
[39]
HANNAH M. Biotechnology's great divide: Strengthening the relationship between patent law and bioethics in the age of CRISPR-Cas9. Minnesota Journal of Law, Science and Technology, 2018, 2(19): 565-606.
[40]
BENJAMIN D E. Protecting society from patently offensive inventions: The risk of reviving the moral utility doctrine. Cornell Law Review, 2004, 3(89): 685-720.
[41]
YANG D Q. Reconstruction of the value, model and rules of patent applicant's obligation of information disclosure. Science and Technology Management Research, 2019, 39(18): 154-163. (in Chinese)
[42]
GEBRU A. Patents, disclosure, and biopiracy. Denver Law Review, 2019, 3(96): 535-584.
[43]
LIU Z X. Typological differentiation of ethical issues in gene editing and its legal regulation. Journal of CUPL, 2023(3): 126-139. (in Chinese)
[44]
LEGALDAILY. After 25 years of negotiations, the WIPO Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge has been successfully concluded. (2024-05-27) [2024-06-10]. http://www.legaldaily.com.cn/index_article/content/2024-05/27/content_9001814.html. (in Chinese)
[45]
WIPO declares war on “biopiracy”. (2024-05-20) [2025-02-17]. https://baijiahao.baidu.com/s?id=1799539042336559753&wfr=spider&for=pc. (in Chinese)
[46]
CONTRERAS J L, SHERKOW J S. CRISPR, surrogate licensing, and scientific discovery. Science, 2017, 355(6326): 698-700.
[47]
ROBERT K M. A note on science and democracy. Journal of Legal and Political Sociology, 1942, 1&2(1): 115-126.
[48]
LEDFORD H. Bitter fight over CRISPR patent heats up. Nature, 2016, 529(7586): 265.
[49]
WANG Y, JIA L N. The coordination between exclusive intellectual property and social public interests: in view of the open source movement. Science and Technology Management Research, 2015, 35(16): 160-163, 174. (in Chinese)
[50]
DORIAN D, RUCHIKA A, MATTHEW S, DEBORAH K M. Revisiting open source. International In-House Counsel Journal, 2018, 42(11): 1-12.
[51]
DAN B, JOSH L, MICHAEL M. Open source genomics. Boston University Journal of Science & Technology Law, 2002, 1(8): 254-271.
[52]
ZHANG B S, QIAO Y M. The dilemma and solutions of open source protection for agricultural plant genetic resources. Research on Rule of Law, 2020(3): 97-105. (in Chinese)
[53]
MICHAEL A E. Open source and innovative copyright. IPL Newsletter, 2004, 3(22): 30-34.
[54]
LIU X X, SHEN D L. Analysis on the intellectual property protection of genetically modified organisms technology. Chinese Bulletin of Life Sciences, 2015, 27(2): 107-112. (in Chinese)
Scientia Agricultura Sinica
Pages 831-839
Cite this article:
XU Y. The Dilemma and Way Out of Patent Regulation for Gene-Edited Crops. Scientia Agricultura Sinica, 2025, 58(5): 831-839. https://doi.org/10.3864/j.issn.0578-1752.2025.05.001
Metrics & Citations  
Article History
Copyright
Return